Sunshine Biopharma announces release of research findings press statement
SBFM•Research findings on MR1-114 and SARS-CoV-2 variants
Sunshine Biopharma disclosed publication in Journal of Medicinal Chemistry on PLpro inhibitor MR1-114 targeting SARS-CoV-2 variants.
- The study reported nanomolar in vitro potency across multiple variants.
- Oral dosing showed efficacy in a SARS-CoV-2 mouse model.
- The publication cited high oral bioavailability.
- Lung enrichment was observed in mice and rats.
Paper: https://pr.report/nwxn
